News J&J shares data on would-be blockbuster antidepressant Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.